Journal issues > Issue 6, October 2020 > Biosimilars in oncology – Part I: The principles of biosimilars

Biosimilars in oncology – Part I: The principles of biosimilars

By: E. Moorkens , Y. Vandenplas MSc, T. Barcina Lacosta MSc, L. Barbier , AG. Vulto

SUMMARY

Equally safe and effective alternatives to biological reference products, biosimilars, can lead to lowered treatment costs and higher patient access. With the arrival of biosimilars in the treatment of cancer (i.e., trastuzumab, rituximab, bevacizumab), it is important that oncologists gain confidence to adopt biosimilars in clinical practice. This article, the first in a series of two, emphasizes the need for biosimilars to create a competitive and sustainable biologicals market, highlights key concepts of the regulatory approval pathway of biosimilars, explains what key challenges biosimilars are facing, and what actions have been undertaken in Belgium to increase their use. We conclude with some recommendations.

(BELG J MED ONCOL 2020;14(6):280-5)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top